Regulatory FDA clears Orca’s cell therapy Tregzi for GvHD PharmaphorumOrca becomes a commercial-stage biotech with the approval of Tregzi, a cell therapy to prevent a serious complication of stem cell transplants.HematologyRead full story pharminent July 1, 2026 (Last updated: July 2, 2026) Pharmaphorum Orca becomes a commercial-stage biotech with the approval of Tregzi, a cell therapy to prevent a serious complication of stem cell transplants. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly’s Jaypirca Wins CHMP Opinion for CLL Across All LinesNext: Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail Related Stories Regulatory Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program pharminent July 1, 2026 Regulatory Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail pharminent July 1, 2026 Regulatory Viridian wins FDA approval for Lumvoa for thyroid eye disease pharminent June 29, 2026
